These results revealed an underlying FTO‐IGF2BP1/2 m6A regulatory mechanism of FOS expression in EBVaGC and partially accounted for the promoting effect of IGF2BP1/2 on EBVaGC cell metastasis, providing a promising therapeutic strategy for targeting FOS and dampening metastasis in GC. This evidence concerns the gene FOS and gastric cancer.